Phase II study supports potential for Roche ’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
Roche today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ ® (atezolizumab) plus Avastin® (bevacizumab) and TECENTRIQ monotherapy to sunitinib alone in people with previously untreated, locally advanced or metastatic renal cell carcinoma (mRCC).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer & Oncology | Carcinoma | Kidney Cancer | Pharmaceuticals | Renal Cell Carcinoma | Study